Back to News
Market Impact: 0.5

Cardinal (CAH) Upgraded to Buy: Here's What You Should Know

CAHHIMS
Corporate EarningsAnalyst EstimatesAnalyst InsightsCompany FundamentalsHealthcare & BiotechInvestor Sentiment & Positioning
Cardinal (CAH) Upgraded to Buy: Here's What You Should Know

Cardinal Health (CAH) has been upgraded to a Zacks Rank #2 (Buy), reflecting a 2.2% increase in its Zacks Consensus Estimate for fiscal year 2026 earnings per share over the past three months. This upward revision in earnings estimates, a significant driver of institutional investor sentiment and near-term stock price movements, positions CAH in the top 20% of Zacks-covered stocks. The company is projected to earn $9.41 per share for the fiscal year ending June 2026, implying potential for near-term stock appreciation.

Analysis

Cardinal Health (CAH) has been upgraded to a Zacks Rank #2 (Buy), a quantitative signal driven by a positive trend in earnings estimate revisions. The Zacks Consensus Estimate for the company has increased by 2.2% over the past three months, a key indicator that often precedes near-term stock price movements as institutional investors adjust their valuation models. This upgrade places CAH in the top 20% of stocks covered by the Zacks system, suggesting a superior earnings outlook relative to the broader market. The article highlights that for the fiscal year ending June 2026, CAH is expected to earn $9.41 per share. While the recent revision trend is positive, it is critical to note that this forecast is unchanged compared to the prior year's reported figure, implying flat year-over-year earnings growth for that period.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment